MedPath

10 Clinical Trials Of 2024 – Hits, Misses And Some In Between

2024 saw several impactful clinical trial readouts, with Scrip highlighting the top 10 stories that captured the most attention over the year.

While quieter than some recent years, 2024 did produce several clinical trial readouts destined to have an impact on their respective markets. Here, in roughly chronological order, Scrip takes a look at the 10 clinical stories that got readers clicking the most over the past 12 months.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Key Clinical Trial Outcomes of 2024: HIV PrEP, SMA, Obesity, and Alzheimer's Disease

Gilead's lenacapavir demonstrated near-perfect efficacy as a twice-yearly injectable for HIV PrEP in Phase III trials, offering a promising alternative to daily oral treatments.
Scholar Rock's apitegromab met its primary endpoint in a Phase III SMA trial, showing statistically significant and clinically meaningful improvements in motor function.

Landmark Clinical Trials of 2024: Advancements in Cancer, Metabolic Diseases, and Infectious Diseases

Moderna and Merck's mRNA-4157 combined with pembrolizumab significantly reduced melanoma recurrence risk by 44% compared to pembrolizumab alone, marking a leap in personalized cancer treatment.
Nivolumab combined with chemotherapy showed a 92% two-year progression-free survival rate in advanced Hodgkin lymphoma, offering a safer, more effective treatment option.

Pharmaceutical R&D Highlights: Key Clinical Updates from November 2024

The FDA approved 50 new molecular entities in 2024, marking a significant year for drug discovery and development across various therapeutic areas.
Clinical trials have seen notable outcomes for key drug candidates, influencing treatment paradigms and offering new hope for patients with unmet medical needs.

October 2024 Clinical Compound Updates: Trial Results and Regulatory Decisions

Several key clinical trial results were announced in October 2024, impacting potential new drug approvals and treatment strategies across various therapeutic areas.
Regulatory decisions, including FDA approvals and drug withdrawals, have reshaped the pharmaceutical landscape, influencing market access and patient care.

October Research Roundup: Transfusions, Smoking Cessation, and More

A study on traumatic brain injury patients suggests that while statistically insignificant, a liberal transfusion strategy may be clinically beneficial, warranting further research.
A smoking cessation program in UK emergency departments, including e-cigarette starter kits and counseling, showed a 3% absolute improvement in abstinence at 6 months.

Alzheimer's Disease and Gene Therapy Clinical Trials Show Promise with Novel Approaches

Over 120 Alzheimer's Disease treatment therapies are under development globally, targeting various mechanisms of action and routes of administration.
Gene therapy is emerging as a potential treatment strategy, with over 300 gene therapy drugs in the pipeline for various diseases, including neurological disorders.

TCT 2024 to Showcase Groundbreaking Cardiovascular Research

TCT 2024 will feature 25 late-breaking clinical trials, presenting novel interventions, drugs, and techniques for cardiovascular disease treatment.
The EARLY TAVR trial examines transcatheter aortic valve replacement for asymptomatic severe aortic stenosis, potentially changing treatment paradigms.

Global Dementia Clinical Trial Landscape Analyzed in New Report

A new report analyzes the global landscape of clinical trials for dementia, providing an overview of trial numbers and average enrollment across top countries.
The report covers clinical trials by region, country (G7 & E7), phase, trial status, endpoint status, and sponsor type, offering a comprehensive view of the research efforts.

Oncology Dominates Planned and Expected Clinical Trials in 2024

Oncology leads as the top therapy area for both planned and expected clinical trials in 2024, indicating a strong focus on cancer research and development.
Phase II trials are the most prevalent among planned trials for 2024, with a majority sponsored by industry players like Novartis.

Landmark Clinical Trials of 2024: Promising Advances in Cancer, Malaria, and Genetic Diseases

AstraZeneca's trastuzumab deruxtecan shows a 73.3% intracranial response rate in breast cancer patients with brain metastases, offering a potential new treatment option.
Oxford University's malaria vaccine, R21/Matrix-M, demonstrates a 78% efficacy rate in young African children, marking a significant improvement over existing vaccines.

Reference News

[1]
10 Clinical Trials Of 2024 – Hits, Misses And Some In Between - Citeline News & Insights
insights.citeline.com · Jan 6, 2025

2024 saw several impactful clinical trial outcomes, quieter than recent years but with significant market implications. ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy